Summary The pharmacological interest in lonidamine is related to its ability to enhance the cytotoxic effects of several DNA-damaging antitumour agents. This study was undertaken to better understand the in vivo interaction between lonidamine and cisplatin in the treatment of human tumour xenografts, including three carcinoma models characterized by a different responsiveness to cisplatin, in spite of the presence of a wild-type p53 gene in all tumours. The drug combination was more effective in tumour growth inhibition than cisplatin alone against MX-1 breast carcinoma and A2780 ovarian carcinoma, both highly responsive to cisplatin, whereas no influence of lonidamine was observed on anti-tumour activity of cisplatin in the treatment of the relatively resistant IGROV-1 ovarian carcinoma. As cisplatin activity is related to induction of apoptosis, the modulation of drug-induced apoptosis by lonidamine was investigated. Under conditions in which lonidamine itself had negligible effects on tumour growth and apoptosis, the modulating agent stimulated the apoptotic response induced by cisplatin in the responsive but not in the resistant tumours. Tumour response was dependent not only on the drug activation of apoptosis, but mainly on the persistence over time of the event. In the breast carcinoma MX-1, hypersensitive to cisplatin and to the lonidamine+cisplatin combination, the efficacy of drug treatment was associated with phosphorylation of bcl-2 followed by down-regulation of the protein. Lonidamine itself caused a delayed phosphorylation of bcl-2. These results are consistent with the interpretation that lonidamine is effective in modulating biochemical factors involved in regulation of apoptosis.
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Keywords: lonidamine; cisplatin; apoptosis; bcl-2; p53 Lonidamine (LND) is a dichlorinated derivative of indazole-3-carboxylic acid, which has been described as an inhibitor of energy metabolism (Silvestrini, 1991) . A selective action of LND on tumour cells has been attributed to its inhibitory effect on mitochondria-bound hexokinase, which is present in tumour cells but not in normal differentiated cells (Hume and Weidemann, 1979; Floridi et al, 1981) . Studies on different tumour cell lines have shown increased cytotoxic efficacy of DNA-damaging antitumour drugs when combined to LND (Chitnis and Adwankar, 1986; Zupi et al, 1986; Raaphorst et al, 1990; Teicher et al, 1991; Zaffaroni et al, 1994) . In the human MX-1 mammary tumour xenografted in nude mice, we recently demonstrated a therapeutic advantage for LND combined to cisplatin (Pratesi et al, 1996) . The cellular and molecular basis of the interaction remains to be determined. At the cellular level, the synergism could be related to a specific interference of LND with energy-dependent DNA-repair processes subsequent to cisplatin-induced DNA damage (Hahn et al, 1984) . Such an effect could result in a fixation of DNA damage, thus activating a cascade of biochemical events, possibly resulting in cell death by apoptosis. Indeed, apoptosis is a major mode of cell death in response to DNA-damaging treatment (Kerr et al, 1994) , and a correlation between apoptotic death and tumour sensitivity to drugs has been documented in some in vitro systems (Wu and El-Deiry, 1996) . We recently reported that human ovarian cancer cell lines selected for resistance to cisplatin have reduced susceptibility to apoptosis induction after cytotoxic treatment, as a consequence of loss of wild-type p53 function (Perego et al, 1996) . A correlation between apoptosis and cellular sensitivity has also been documented for LND, but LND-induced apoptosis is not mediated by the p53 gene (Del Bufalo et al, 1996) .
The aim of the present study was to investigate further the interaction of LND and cisplatin in human carcinoma systems characterized by different responsiveness to cisplatin. One relatively resistant (the ovarian IGROV-1) and two sensitive (the ovarian A2780 and the mammary MX-1) carcinomas were used. All tumours, maintained by serial passages in nude female athymic mice, were characterized by wild-type p53 (Perego et al, 1996; Arcamone et al, 1997; Caserini et al, 1997) . In particular, the study investigated the effect of drug treatment on tumour apoptosis induction and its correlation to tumour response. The results of our study showed that LND, under conditions in which alone it had a negligible effect, potentiated cisplatin efficacy only in tumours highly responsive to cisplatin and that, in these sensitive tumour systems, LND enhanced the apoptotic response induced by treatment with the cytotoxic agent and maintained it for a long time. Moreover, our results show that both cisplatin and LND induce phosphorylation of bcl-2 protein. according to the same route and schedule used for LND in the same experiment. Tumour-bearing mice were treated according to two schedules: (a) single i.p. cisplatin treatment followed by 20 daily LND treatments (50 mg kg-') according to the same route and (b) three i.v. cisplatin injections, once a week for 3 consecutive weeks, each one followed by five administrations of LND per os (100 mg kg-'). The same dose of cisplatin, 6 mg kg-' per injection, was used in the two schedules. A LND dose of 50 mg kg-' i.p. and 100 mg kg-' per os had similar efficacy in our previous study (Pratesi et al, 1996) . In both schedules, LND was delivered after cisplatin treatment because this drug sequence was found to be the optimal one for the combination (Cividali et al, 1992) . Drug activity was assessed as: (a) the percentage of tumour volume inhibition (TVI%), calculated by the formula: TVI% = l00-(tV/cVxlOO), where tV is the mean TV of treated tumours and cV that of control tumours (the day on which TVI% was calculated is reported in Table 1 ); (b) the log,0 cell kill achieved by the drug treatment, according to the formula: T -C/DT x 3.32, where T is the mean time (days) required for the treated tumours and C the mean time for the control tumours to reach an established volume (see Table 1 ) and DT is the doubling time of control tumours. A tumour was considered responsive when the drug treatment achieved a loglo cell kill > 1.
British Journal of Cancer (1998) Deaths occurring in treated mice before the death of the first control mouse were ascribed to toxic effects.
Determination of mitotic and apoptotic indexes
Tumour-bearing mice were treated with cisplatin and LND, alone or in combination. Cisplatin was given as a single i.p. injection at the dose of 10 mg kg-1 (which is slightly below the maximumtolerated dose of 12 mg kg-' in our strain of mice); LND (100 mg kg-') was administered orally and daily, starting just after the cisplatin injection. At sequential times after the cisplatin injection (from 1 day on), one mouse per group was sacrificed by cervical dislocation; its two tumours were removed, placed in neutral-buffered formalin and processed for embedding in paraffin blocks. From each tumour block, 2-to 4-micron sections were cut and adhered to poly-L-lysine pretreated slides. Tissue sections were then treated according to the method described by Gavrieli et al (1992) . For the TdT-mediated dUTP nick-end labelling (TUNEL) reaction, the in situ cell death detection POD kit (Boehringer Mannheim, Ingelheim, Germany) was used. The final staining was performed using a DAB (Sigma, St Louis, MO, USA) solution. Sections were counterstained with haematoxylin. Apoptotic index (AI) was determined as indicated in the figure legends, using a light microscope at 400 x magnification. Successive sections of the same tumour samples were stained with the standard haematoxylin-eosin method to determine the mitotic index (MI), which is expressed as for the Al. Scoring of histological tumour sections was conducted without knowledge of the results of the tumour growth-inhibition studies.
Western blot analysis
Tumour samples were minced and suspended in 500,l of Laemmli buffer (Laemmli, 1970) ; suspensions were completely disrupted using a tissue Potter and successively sonicated for 1 min at low intensity. Debris was sedimented at 12 000 r.p.m. for 10 min at 4°C. Supematants containing protein extracts were collected, and a 1:10 volume of P-mercaptoethanol was added; they were then boiled for 3 min and stored at -80°C. Protein concentration was determined using the BCA Protein Assay Reagent (Pierce, Rockford, IL USA). Aliquots of 80 gg were sizeseparated by SDS-PAGE (12% gel) and transferred to a nitrocellulose filter (BioRad Lab, Segrate, Italy) by electroblotting. Immunodetection was carried out using an anti-bcl-2 (Santa Cruz Biotechnology, Segrate, Italy) polyclonal antibody (1:1000), and blots were successively developed with peroxidase anti-rabbit antibody (1:2000) using the enhanced chemiluminescence (ECL) detection kit (Amersham, Little Chalfont, UK). The phosphorylated form of bcl-2 protein was detected as a slower mobility form as previously described (Haldar et al, 1995) .
Statistical analysis
The statistical significance of the differences in tumour volumes and Al values between cisplatin-and cisplatin + LND-treated tumours was tested using the Student's t-test (two-tailed). P-values were considered to be significant when less than or equal to 0.05.
RESULTS

Chemotherapy studies
The influence of LND on cisplatin anti-tumour efficacy in human tumour xenografts is reported in Table 1 . The MX-1 tumour was very sensitive to cisplatin treatment, as tumours treated with a single suboptimal dose disappeared by day 15. However, some tumours regrew after 40-50 days (Pratesi et al, 1996) . The enhancement induced by LND on this tumour was dramatic, as all mice were cured by the combination (no tumour regrowth up to 100 days). A significant enhancement of cisplatin anti-tumour activity by LND was achieved also in A2780 tumour-bearing mice, using either treatment schedules. As expected, in this sensitive tumour, British Journal of Cancer (1998) Cancer Research Campaign 1998
Therapeutic synergism of lonidamine and cisplatin 437 cisplatin activity was higher when the optimal dose (6 mg kg-' for three times) instead of a suboptimal one (6 mg kg-', single treatment) was administered to mice. Conversely, only a marginal increase of drug efficacy was observed in the naturally resistant IGROV-1 tumour between one and three cisplatin treatments, nor did LND influence the low anti-tumour activity. LND was better tolerated after oral administration than i.p. treatment.
Induction of apoptosis
The kinetics of apoptosis induction by drug treatment was studied in tumour tissues, and the time course and the extent of apoptosis induction in the three tumour lines is reported in Figure 1 . Established MX-1 tumours (450-mm3 mean volume) were treated with 10 mg kg-' of cisplatin, and the Al was calculated in histological sections of tumours at sequential times (from day 1 to day 12 after treatment). In cisplatin-treated tumours, the percentage of apoptotic cells was similar to that of untreated controls on day 1 and rose to high values from day 5 onwards. The Al in tumours treated with cisplatin + LND (given daily) followed the same kinetics as that of cisplatin-treated tumours but was generally higher (most evident on day 10). The increase in Al of treated tumours was persistent, as the Al was still higher than that of control tumours on the last day of observation (day 12). No evaluation could be made at longer times for tumour disappearance. Untreated control tumours presented a low Al (basal level 0.4 ± 0.2), which remained unchanged up to day 12. LND alone did not modify the Al compared with untreated controls. Mice bearing A2780 tumours were treated when tumour volume was around 350 mm3. Spontaneous tumour apoptosis was higher (basal level 1.4 ± 0.2) than that in MX-1 tumours. Again, LND alone was ineffective as an apoptosis inducer at all times. In cisplatin-treated tumours, a prompt increase in Al had already been induced at 1 day after treatment, but values returned to basal levels by day 6. Conversely, in the cisplatin + LND-treated tumours the high level of Al lasted much longer, and the level at day 6 was significantly different between the two groups (P < 0.001).
In IGROV-1 tumour-bearing mice, treated when tumours were about 200 mm3, basal apoptosis values were the highest among the three tumours tested (basal level 1.8 ± 0.5). In spite of tumour cell ability to activate spontaneous apoptosis, cisplatin treatment only marginally increased the Al (less than twofold) and only for a short time (peak level on day 1). Moreover, the Al in tumours treated with the cisplatin + LND combination never exceeded the values of cisplatin-treated tumours. Table 2 summarizes the apoptotic and mitotic levels in the three tumour lines investigated in the study. Mitosis level differed in the tumours and did not correlate with tumour doubling time. The MX-1 tumour, which has the highest MI, was also the most responsive tumour to cisplatin treatment. Considering the apoptosis level induced by cisplatin treatment, it is noteworthy that the very sensitive MX-1 tumour cells keep dying from apoptosis for long time (the Al was still higher than in control tumours after 12 days). Moreover, the duration of apoptosis correlated well with tumour response to treatment. Comparing the time course of apoptosis in MX-1 and A2780 tumours, the influence of LND on apoptosis induced by cisplatin appeared to be related more to maintenance than to the peak level of the apoptotic event.
Bcl-2 expression and modulation Although all three tumours were characterized by a wild type p53, only MX-1 overexpressed bcl-2 protein. Thus, only in this tumour model, modulation of the anti-apoptic protein was studied after treatment with cisplatin (single i.v. 10 mg kg-') and/or LND (daily per os, 100 mg kg-1). Five and 10 days after cisplatin treatment (day 0), one mouse per group was sacrificed and its two tumours were excised and processed for Western blot analysis of bcl-2 protein (Figure 2) . At 5 days, cisplatin and cisplatin + LND treatments induced phosphorylation of the protein. This change was associated with an increased expression of bax protein (not shown). Meanwhile, a progressive down-regulation of bcl-2 protein was observed in both groups, which was almost complete at 10 days. Again, a parallel reduction of bax level was detected at this time (not shown). LND alone induced an appreciable increase of the phosphorylated form of bcl-2, which was more evident at 10 days.
DISCUSSION
Our earlier studies on LND as a modulator of anti-tumour activity of cytotoxic agents showed that improvement of the therapeutic efficacy is related to responsiveness of the tumour to the drug used in combination with LND (Pratesi et al, 1996) . Indeed, using a breast carcinoma model, MX-1, which is responsive to cisplatin but resistant to doxorubicin, LND was able to potentiate the activity of cisplatin but exhibited negligible effects on tumour response to doxorubicin treatment. In an attempt to better understand the mechanisms of the enhancement of cisplatin activity in combination with LND, in the present study we extended the investigation to other tumour systems characterized by different tumour responsiveness to cisplatin. Indeed, a synergistic interaction between cisplatin and LND was observed in the two cisplatinresponsive tumours (i.e. MX-1 breast carcinoma and A2780 ovarian carcinoma) but not in the relatively resistant IGROV-1 ovarian carcinoma. The present results are consistent with the interpretation that the nature of the drug interaction is dependent on the intrinsic tumour cell sensitivity to the cytotoxic agent. Based on this preclinical study, when used in combination with cisplatin, LND should be regarded as a potentiating agent rather than as a modulator of drug resistance (Calabresi et al, 1994) .
As, in our experience, tumour responsiveness reflects, at least in part, drug ability to activate an apoptotic response, this study focused on apoptosis induction as a cellular basis of cytotoxic drug potentiation by LND. Previous studies have indicated that p53 gene status is an important determinant of cellular sensitivity to cisplatin (Rusch et al, 1995; Perego et al, 1996; Righetti et al, 1996) . For this reason, only tumour models characterized by wild type p53 were chosen for the study. The responsiveness of MX-1 and A2780 tumours is consistent with p53 gene status. The marginal activity of cisplatin in the treatment of IGROV-1 tumour reflects a relative in vitro resistance of the IGROV-1 cells . The molecular basis of the limited responsiveness of the IGROV-1 tumour is probably related to defence mechanisms (e.g. increased efficiency of the glutathione-dependent system) (Pratesi et al, 1995) rather than an intrinsic resistance to apoptosis activation, as a marked apoptotic response could be achieved after in vitro exposure to cytotoxic levels of DNAdamaging agents (Perego et al, 1996) . This interpretation is consistent with the finding that IGROV-1 cells displayed a significant basal level of apoptosis (Table 2 ). In the responsive tumour systems, the pattern of apoptosis induction could account for the differential tumour sensitivity to cisplatin. In the A2780 tumour, a marked and prompt apoptosis induction was observed; however, the drug-induced effect was transient. Thus, multiple treatments are required to achieve a therapeutic efficacy similar to that produced by a single dose of cisplatin in the hypersensitive tumour MX-1; conversely, in this tumour, apoptosis induced by cisplatin was delayed but very persistent. The very low basal level of apoptosis could reflect the overexpression of the anti-apoptotic protein bcl-2. However, no correlation has been found between bcl-2 levels and response to cisplatin among the tumours tested.
In contrast to cellular response to cisplatin, apoptosis induced in vitro by LND is independent of the p53 gene, as expected for a non-DNA-damaging agent (Del Bufalo et al, 1996) . Based on these observations, a cooperation between p53-dependent and p53-independent apoptotic pathways could account for the synergistic interaction between cisplatin and LND, in terms of tumour growth inhibition and apoptosis induction. In the IGROV-1 tumour, the marginal induction of apoptosis by cisplatin could not achieve the threshold required for an efficient interaction, as LND itself at the dose level used in vivo was not effective as an apoptotic inducer. In contrast, LND-induced biochemical changes, although not resulting in apoptosis, could be relevant in tumour systems in which a marked apoptosis was activated by the DNAdamaging treatment. As a persistent induction of apoptosis was correlated with anti-tumour drug efficacy, it is probable that the daily administration of LND favours activation of the apoptotic process, which appears to be differentially regulated in the responsive tumours but not in the resistant IGROV-I. This interpretation is consistent with the observation that phosphorylation of bcl-2 was a late event after multiple LND treatments. A role of bcl-2 has been implicated in the tumour cell susceptibility to apoptosis (Reed, 1994) . Our study provides evidence that in the MX-I tumour the efficacy of cisplatin treatment was related to phosphorylation of bcl-2 followed by down-regulation. Phosphorylation was enhanced by LND, and this might represent a basis of the synergistic interaction between cisplatin and LND. A marked modulation of bcl-2 by a DNA-damaging agent was an unexpected finding, as no phosphorylation was detected in prostatic tumour cells treated for 24 h with cisplatin (Haldar et al, 1997) . A possible explanation for this discrepancy is that, in contrast to taxol, phosphorylation induced by the DNA-damaging agent is a late event. Indeed, in our in vivo experiments, bcl-2 modulation was found 5-10 days after drug treatment. Our finding that LND itself induced bcl-2 phosphorylatin suggests that the drug may potentiate the cisplatin-induced apoptosis through a mechanism involving inactivation of bcl-2 function and provides new insights into the mechanism of action of LND as an anti-tumour chemotherapy modulator. LND is known to interfere with mitochondria functions (Hume and Weidemann, 1979; Floridi et al, 1981; Sarti et al, 1994) and to alter the outer mitochondrial membrane (Sarti et al, 1994) . Our observations on MX-1 tumour raise the possibility that LND action is mediated by interfering with bcl-2 membrane-stabilizing effect on mitochondria, which is considered critical in the bcl-2 anti-apoptotic role (Kroemer, 1997) .
In conclusion, the present study showed that LND may act as a potentiating agent of cisplatin anti-tumour efficacy, possibly stimulating the apoptotic response induced by the DNA-damaging drug in responsive tumours. Moreover, the combination may produce particularly favourable results in bcl-2-overexpressing tumours.
